CINGW — Cingulate Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1862150 ·
Last close
$0.01
Market Cap
—
52W High
$0.01
52W Low
$0.01
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,414,975 | -5,870,264 | 33,066,321 | 28,402,819 | 9,599,286 |
| Mar 2026 | 0 | — | -7,923,318 | -9,312,089 | 30,861,701 | 25,893,210 | 11,996,835 |
| Dec 2025 | 0 | — | -5,585,948 | -6,272,910 | 15,073,263 | 10,953,383 | 12,564,356 |
| Sep 2025 | 0 | — | -5,995,544 | -7,341,062 | 10,518,892 | 6,118,710 | 7,045,206 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,549,860
Investing CF
$-223,321
Financing CF
$36,147,425
CapEx
$-415,858
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-141,687,120
Inventory
—
Receivables
$53,938
ST Investments
—
EBIT TTM
$-24,154,749
Pretax Income TTM
$-27,714,796
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,938,057 | -22,449,911 | 15,073,263 | 12,564,356 | 2,508,907 | -17,245,182 |
| Dec 2024 | 0 | -15,645,265 | -16,559,605 | 14,864,489 | 7,408,984 | 7,455,505 | -18,451,387 |
| Dec 2023 | 0 | -22,759,304 | -23,534,947 | 3,491,436 | 10,360,865 | -6,869,429 | -15,034,543 |
| Dec 2022 | 0 | -17,502,280 | -17,676,232 | 11,405,057 | 7,523,035 | 3,882,022 | -15,882,808 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
2026-06-16 12:00 · Yahoo
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
2026-09-17 12:05 · Yahoo
CING: Second Quarter Results
2026-08-19 15:13 · Yahoo
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
2026-08-13 12:30 · Yahoo
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
2026-08-11 12:30 · Yahoo
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
2026-07-30 12:30 · Yahoo
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
2026-07-02 12:30 · Yahoo
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
2026-06-04 20:48 · Yahoo
Cingulate Receives Complete Response Letter from FDA for CTx-1301
2026-06-02 12:00 · Yahoo
CING: Building Its Cash Position
2026-05-19 09:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.